Executive interview with Erik Manting PhD, CEO of Mendus

Mendus is a clinical-stage immuno-oncology company focused on the development of off-the-shelf therapies for haematological and solid tumours. The company is at a period of inflection as Mendus progresses its lead cancer vaccine, vididencel, towards pivotal stages of clinical development. Following the promising results of ADVANCE II (testing vididencel as a monotherapy maintenance treatment in acute myeloid leukaemia), Mendus is now exploring the potential synergy between vididencel and oral azacitidine (the current standard of care) in the CADENCE trial, with support from the prestigious Australasian Leukaemia and Lymphoma Group. The cancer vaccine is also being investigated as a potential maintenance therapy in ovarian cancer and updates from the Phase I ALISON trial are expected later this year. In parallel, Mendus’s second asset, ilixadencel, is gearing up to re-enter the clinic (Phase II) with a refreshed strategy, targeting soft tissue sarcomas. More details on the trial plans are expected within Q224, with potential launch in H224.

In this video, CEO Erik Manting provides more colour on all components of Mendus’s pipeline, including the next steps for vididencel as it prepares for the CADENCE trial. He also outlines a potential registrational study in 2025, updated strategy for ilixadencel and the company’s current pre-clinical research activities.